{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:15:41Z","timestamp":1792790141973,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s13318-025-00957-0","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:52:29Z","timestamp":1753815149000},"page":"409-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of the Effect of Ticagrelor Dose Interruption and Treatment Resumption with or without Bolus Doses Through Population PK\/PD Simulation"],"prefix":"10.1007","volume":"50","author":[{"given":"Hiroyoshi","family":"Matsui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Thien Truc","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2447-6113","authenticated-orcid":false,"given":"Eyob","family":"Adane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"957_CR1","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/phar.1477","volume":"34","author":"PP Dobesh","year":"2014","unstructured":"Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2014;34:1077\u201390.","journal-title":"Pharmacotherapy"},{"key":"957_CR2","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","volume":"7","author":"JJJ Van Giezen","year":"2009","unstructured":"Van Giezen JJJ, Nilsson L, Berntsson P, Wissing B-M, Giordanetto F, Tomlinson W, et al. Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7:1556\u201365.","journal-title":"J Thromb Haemost"},{"key":"957_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1755-5922.2009.00096.x","volume":"27","author":"S Husted","year":"2009","unstructured":"Husted S, van Giezen JJJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27:259\u201374.","journal-title":"Cardiovasc Ther"},{"key":"957_CR4","unstructured":"Ticagrelor [Package insert on the internet]. Silver Spring (MD): Food and Drug Administration. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/022433s037lbl.pdf."},{"key":"957_CR5","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720\u2013826.","journal-title":"Eur Heart J"},{"key":"957_CR6","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1161\/CIRCULATIONAHA.121.058519","volume":"145","author":"JS Lawton","year":"2022","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e4-17.","journal-title":"Circulation"},{"key":"957_CR7","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","volume":"151","author":"SV Rao","year":"2025","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151:e771-862.","journal-title":"Circulation"},{"key":"957_CR8","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","volume":"36","author":"D Aradi","year":"2015","unstructured":"Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015;36:1762\u201371.","journal-title":"Eur Heart J"},{"key":"957_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/ehjcvp\/pvae080","volume":"11","author":"U Baber","year":"2025","unstructured":"Baber U, Cao D, Collier T, Sartori S, Dangas G, Angiolillo DJ, et al. Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial. Eur Heart J Cardiovasc Pharmacother. 2025;11:66\u201374.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"957_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1365-2125.2010.03669.x","volume":"70","author":"K Butler","year":"2010","unstructured":"Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol. 2010;70:65\u201377.","journal-title":"Br J Clin Pharmacol"},{"key":"957_CR11","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1517\/14656566.2011.550573","volume":"12","author":"MA Giorgi","year":"2011","unstructured":"Giorgi MA, Cohen Arazi H, Gonzalez CD, Di Girolamo G. Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opin Pharmacother. 2011;12:1285\u201395.","journal-title":"Expert Opin Pharmacother"},{"key":"957_CR12","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1111\/bcp.12026","volume":"75","author":"MT Holmberg","year":"2013","unstructured":"Holmberg MT, Tornio A, Joutsi-Korhonen L, Neuvonen M, Neuvonen PJ, Lassila R, et al. Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. Br J Clin Pharmacol. 2013;75:1488\u201396.","journal-title":"Br J Clin Pharmacol"},{"key":"957_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40262-023-01243-5","volume":"62","author":"C Konecki","year":"2023","unstructured":"Konecki C, Holm M, Djerada Z. Negative impact of ST-segment elevation myocardial infarction and morphine dose on ticagrelor uptake and pharmacodynamics: a population PK\/PD analysis of pooled individual participant data. Clin Pharmacokinet. 2023;62:905\u201320.","journal-title":"Clin Pharmacokinet"},{"key":"957_CR14","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jchromb.2011.06.023","volume":"879","author":"H Sill\u00e9n","year":"2011","unstructured":"Sill\u00e9n H, Cook M, Davis P. Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS\/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:2315\u201322.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"957_CR15","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"PA Gurbel","year":"2009","unstructured":"Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study. Circulation. 2009;120:2577\u201385.","journal-title":"Circulation"},{"key":"957_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/bcp.13812","volume":"85","author":"M \u00c5strand","year":"2019","unstructured":"\u00c5strand M, Amilon C, R\u00f6shammar D, Himmelmann A, Angiolillo DJ, Storey RF, et al. Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. Br J Clin Pharmacol. 2019;85:413\u201321.","journal-title":"Br J Clin Pharmacol"},{"key":"957_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jcin.2022.01.300","volume":"15","author":"B Redfors","year":"2022","unstructured":"Redfors B, Kirtane AJ, Liu M, Musikantow DR, Witzenbichler B, Rinaldi MJ, et al. Dual antiplatelet therapy discontinuation, platelet reactivity, and adverse outcomes after successful percutaneous coronary intervention. JACC Cardiovasc Interv. 2022;15:797\u2013806.","journal-title":"JACC Cardiovasc Interv"},{"key":"957_CR18","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1016\/j.chest.2022.07.025","volume":"162","author":"JD Douketis","year":"2022","unstructured":"Douketis JD, Spyropoulos AC, Murad MH, Arcelus JI, Dager WE, Dunn AS, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest. 2022;162:e207\u201343.","journal-title":"Chest"},{"key":"957_CR19","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","volume":"136","author":"DJ Angiolillo","year":"2017","unstructured":"Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International Expert Consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation. 2017;136:1955\u201375.","journal-title":"Circulation"},{"key":"957_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13019-021-01521-y","volume":"16","author":"S Diab","year":"2021","unstructured":"Diab S, Arazi M, Sternik L, Raanani E, Kachel E, Grosman-Rimon L, et al. Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes. J Cardiothorac Surg. 2021;16:139.","journal-title":"J Cardiothorac Surg"},{"key":"957_CR21","unstructured":"Transit compartments and Weibull absorption | Mlxtran. [cited 2024 Sep 25]. https:\/\/mlxtran.lixoft.com\/examples\/transit-compartments-weibull-absorption\/."},{"key":"957_CR22","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1016\/j.jcin.2024.08.027","volume":"17","author":"DJ Angiolillo","year":"2024","unstructured":"Angiolillo DJ, Galli M, Alexopoulos D, Aradi D, Bhatt DL, Bonello L, et al. International Consensus statement on platelet function and genetic testing in percutaneous coronary intervention: 2024 update. JACC Cardiovasc Interv. 2024;17:2639\u201363.","journal-title":"JACC Cardiovasc Interv"},{"key":"957_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/eurheartj\/ehv381","volume":"37","author":"EC Hansson","year":"2016","unstructured":"Hansson EC, Jid\u00e9us L, \u00c5berg B, Bjursten H, Dreifaldt M, Holmgren A, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J. 2016;37:189\u201397.","journal-title":"Eur Heart J"},{"key":"957_CR24","unstructured":"Cangrelor [Package insert on the internet]. Silver Spring (MD): Food and Drug Administration. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/204958Orig1s003lbl.pdf."},{"key":"957_CR25","doi-asserted-by":"publisher","first-page":"EVIDoa2100047","DOI":"10.1056\/EVIDoa2100047","volume":"1","author":"DL Bhatt","year":"2022","unstructured":"Bhatt DL, Pollack CV, Mazer CD, Angiolillo DJ, Steg PG, James SK, et al. Bentracimab for ticagrelor reversal in patients undergoing urgent surgery. NEJM Evid. 2022;1:EVIDoa2100047.","journal-title":"NEJM Evid."},{"key":"957_CR26","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jtcvs.2013.12.011","volume":"148","author":"V Mannacio","year":"2014","unstructured":"Mannacio V, Meier P, Antignano A, Di Tommaso L, De Amicis V, Vosa C. Individualized strategy for clopidogrel suspension in patients undergoing off-pump coronary surgery for acute coronary syndrome: a case-control study. J Thorac Cardiovasc Surg. 2014;148:1299\u2013306.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"957_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jacc.2010.01.062","volume":"56","author":"RF Storey","year":"2010","unstructured":"Storey RF, Bliden KP, Patil SB, Karunakaran A, Ecob R, Butler K, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET\/OFFSET study. J Am Coll Cardiol. 2010;56:185\u201393.","journal-title":"J Am Coll Cardiol"},{"key":"957_CR28","first-page":"633","volume":"51","author":"EC Hansson","year":"2017","unstructured":"Hansson EC, Malm CJ, Hesse C, Hornestam B, Dellborg M, Rexius H, et al. Platelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgery. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio Thorac Surg. 2017;51:633\u20137.","journal-title":"Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio Thorac Surg."},{"key":"957_CR29","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40262-015-0290-2","volume":"54","author":"R Teng","year":"2015","unstructured":"Teng R. Ticagrelor: pharmacokinetic, pharmacodynamic and pharmacogenetic profile: an update. Clin Pharmacokinet. 2015;54:1125\u201338.","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00957-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00957-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00957-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T08:42:39Z","timestamp":1757320959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00957-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["957"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00957-0","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"25 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current work did not receive any funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Data sets generated during the current study are available from the corresponding author upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Hiroyoshi Matsui, Le Thien Truc Pham & Eyob Adane have no financial or non-financial interests that are directly or indirectly related to the work submitted for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}